Abstract:
OBJECTIVE To mine and analyze the adverse drug reaction(ADR) of arsenic trioxide and explore its potential adverse reactions, so as to provide reference for the safe and rational use of drugs in clinical practice.
METHODS Relative ADR reports of arsenic trioxide from the first quarter of 1998 to the second quarter of 2023 in the FDA Adverse Event Reporting System(FAERS) database were collected; conduct data mining by utilizing the reporting odds ratio method within the proportional imbalance method and the comprehensive criteria method of the UK Medicines and Healthcare Products Regulatory Agency. ADR reports were described and classified according to the system organ class(SOC) and preferred term(PT) in the Medical Dictionary for Regulatory Activities.
RESULTS A total of 2 084 cases of ADR reports related to arsenic trioxide were retrieved; involving 924 male patients and 841 female patients. There were more patients aged ≥35(1 276 cases), the main reporting country being the United States(429 cases, 20.59%), and a total of 1 914 cases of severe ADR, accounting for 91.84%, mainly leading to hospitalized(711 cases, 34.12%) and died(296 cases, 14.20%). A total of 358 ADR signals were excavated, involving 24 types of SOC, mainly including investigations(1 169 cases, 21.17%) and nervous system disorders(361 cases, 6.54%); the main ADR with a high frequency of occurrence were electrocardiogram QT prolonged, differentiation syndrome, pyrexia, dyspnoea, and other PTs, the drug instructions didn’t include pneumonia, white blood cell count decreased, and disease progression. The signal intensity ranking high was mainly characterized by differentiation syndrome, haematopoietic neoplasm, hyperleukocytosis and other PT, and myopericarditis, septic embolus, and central nervous system haemorrhage were not included in the drug instructions.
CONCLUSION Arsenic trioxide can cause a high proportion of serious ADR, and attention should be paid to ADR that occur frequently and are not included in the instructions. Before, during, and during the follow-up phase of medication treatment, relevant monitoring and reporting work should be carried out, to effectively ensure the safety of medication for patients.